Meyeon Park, MD, MAS

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Phone415-514-1122
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of PennsylvaniaM.D.2006School of Medicine
    Yale-New Haven Hospital2009Internal Medicine Residency
    University of California, San FranciscoM.A.S. in Clinical Research2012 Graduate Division (Advanced Training in Clinical Research)
    University of California, San Francisco2013Nephrology fellowship
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    National PKD Foundation2017Physician Gratitude Award
    Doris Duke Charitable Foundation2015  - 2018Clinical Scientist Development Award
    NIH NIDDK2013  - 2018K23 Career Development Award
    UCSF CTSI2015  - 2016Pilot for Junior Investigators in Basic and Clinical/Translational Sciences
    UCSF Department of Medicine2014  - 2015Centers of Excellence in Patient Research Pilot Award

    Collapse Overview 
    Collapse Overview
    My research focuses on patient outcomes in genetic kidney diseases including polycystic kidney disease and APOL1-mediated kidney disease. I am the medical director of the UCSF PKD Center of Excellence and principal investigator of the UCSF Cardiovascular Risk After Kidney Transplantation (CARAKTER) study.

    EDUCATION
    College: Harvard College
    Medical School: University of Pennsylvania School of Medicine
    Other Graduate Training: University of California, San Francisco, MAS
    Internal Medicine Residency: Yale-New Haven Hospital
    Nephrology Fellowship: University of California, San Francisco

    Collapse Research 
    Collapse Research Activities and Funding
    Living Donor Extended Time Outcomes (LETO) Study
    NIH R01DK120551Jun 1, 2019 - May 31, 2024
    Role: Co-Principal Investigator
    (1/1) Maximizing geographic and scientific reach through a Northern California APOLLO Network: application for Clinical Center
    NIH U01DK116043Sep 25, 2017 - May 31, 2022
    Role: Co-Principal Investigator
    Why do patients with cardiovascular disease develop kidney injury and disease?
    NIH K23DK099238Sep 1, 2013 - Sep 30, 2018
    Role: Principal Investigator
    Subclinical and clinical heart disease and the effect on kidney injury and diseas
    NIH F32DK093231Jan 1, 2012 - Dec 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Patient Experience with Genetic Testing in ADPKD. Journal of the American Society of Nephrology. 2024 Oct 1; 35(10S):10.1681/asn.2024c87bewxv. Etwaru ED, Gao GY, Park PM. .
      View in: Publisher Site   Mentions:
    2. Initial Experience of Metabolic Imaging with Hyperpolarized [1-13C]pyruvate MRI in Kidney Transplant Patients. ArXiv. 2024 Sep 10. Liu X, Lai YC, Cui D, Kung SC, Park M, Zoltan L, Larson PEZ, Wang ZJ. PMID: 39314508; PMCID: PMC11419194.
      View in: PubMed   Mentions:
    3. Initial Experience of Metabolic Imaging With Hyperpolarized [1-13C]pyruvate MRI in Kidney Transplant Patients. J Magn Reson Imaging. 2024 Sep 06. Liu X, Lai YC, Cui D, Kung SC, Park M, Laszik Z, Larson PEZ, Wang ZJ. PMID: 39239784.
      View in: PubMed   Mentions:    Fields:    
    4. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry. Kidney Med. 2024 May; 6(5):100813. Hoover E, Holliday V, Merullo N, Oberdhan D, Perrone RD, Rusconi C, Park M, Phadnis MA, Thewarapperuma N, Dahl NK. PMID: 38689835; PMCID: PMC11059322.
      View in: PubMed   Mentions:
    5. All Patients with ADPKD Should Undergo Screening for Intracranial Aneurysms: PRO. Kidney360. 2024 Apr 01; 5(4):492-494. Eswarappa MS, Park M. PMID: 37990366; PMCID: PMC11093534.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    6. ADPKD Comorbid Conditions at a PKD-Focused Center. Journal of the American Society of Nephrology. 2023 Nov 1; 34(11S):936-936. Chao CA, Gao GY, Etwaru ED, Park PM. .
      View in: Publisher Site   Mentions:
    7. 41-Year-Old Male with Sub-Acute Encephalopathy, Seizures, and End Stage Renal Disease: A Unifying Diagnosis and Response to Therapy. Neurohospitalist. 2024 Jan; 14(1):69-73. Wais T, Ibarra KP, Sudarshana DM, Eswarappa M, Park M, Gallagher RC, Tsui B, Teixeira S, Josephson SA, Richie M. PMID: 38235033; PMCID: PMC10790610.
      View in: PubMed   Mentions:
    8. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. Adv Kidney Dis Health. 2023 05; 30(3):228-235. Ackley W, Dahl NK, Park M. PMID: 37088525.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Barriers and facilitators to the transplant process among patients living with polycystic kidney disease: a qualitative Approach. BMC Nephrol. 2023 05 01; 24(1):119. Smith J, Harris OO, Adey D, Park M. PMID: 37127564; PMCID: PMC10150665.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Abstract P140: Potential Mediators for Cardiovascular Benefits of Novel Diabetes Medications: A Meta-Regression Analysis. Circulation. 2023 Feb 28; 147(Suppl_1):ap140-ap140. Valadez VJ, Tahsin TM, Masharani MU, Park PM, Hunink HM, Yeboah YJ, Li LL, Weber WE, Li LY, Berkalieva BA, Avezaat AL, Max MW, Fleischmann FK, Ferket FB. .
      View in: Publisher Site   Mentions:
    11. Post-transplant ejection fraction and renal failure in cardiac transplant recipients: An analysis of the OPTN database. Clin Transplant. 2023 02; 37(2):e14881. Lai M, Aras MA, Park M. PMID: 36504467.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Much Ado About Something: The Clinical Pattern of Tolvaptan-Associated Liver Injury in Participants With ADPKD. Am J Kidney Dis. 2023 03; 81(3):259-260. Postalcioglu M, Cullaro G, Park M. PMID: 36528464.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Experience With Genetic Testing at a Large Polycystic Kidney Disease-Focused Program. Journal of the American Society of Nephrology. 2022 Nov 1; 33(11S):150-150. Chao CA, Gao GY, Jiang JJ, Etwaru ED, Osunde OA, Varanasi VL, Gluck GS, Loeb LG, Park PM. .
      View in: Publisher Site   Mentions:
    14. Tolvaptan Use at a Large PKD-Focused Program. Journal of the American Society of Nephrology. 2022 Nov 1; 33(11S):150-150. Chao CA, Gao GY, Jiang JJ, Osunde OA, Etwaru ED, Varanasi VL, Gluck GS, Park PM. .
      View in: Publisher Site   Mentions:
    15. 871-P: Weight Change as Mediator for Cardiovascular Benefits of Novel Diabetes Medications: A Meta-Regression Analysis. Diabetes. 2022 Jun 1; 71(Supplement_1). RODRIGUEZ-VALADEZ RJ, HUNINK HM, MASHARANI MU, YEBOAH YJ, PARK PM, LI LL, WEBER WE, LI LY, BERKALIEVA BA, MAX MW, FLEISCHMANN FK, FERKET FB. .
      View in: Publisher Site   Mentions:
    16. 872-P: Cardiovascular Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Meta-Regression Analysis of 17 Randomized Trials. Diabetes. 2022 Jun 1; 71(Supplement_1). RODRIGUEZ-VALADEZ RJ, HUNINK HM, MASHARANI MU, YEBOAH YJ, PARK PM, LI LL, WEBER WE, LI LY, BERKALIEVA BA, MAX MW, FLEISCHMANN FK, FERKET FB. .
      View in: Publisher Site   Mentions:
    17. Design and Basic Characteristics of a National Patient-Powered Registry in ADPKD. Kidney360. 2022 08 25; 3(8):1350-1358. Hoover E, Perrone RD, Rusconi C, Benson B, Dahl NK, Gitomer B, Manelli A, Mrug M, Park M, Seliger SL, Phadnis MA, Thewarapperuma N, Watnick TJ. PMID: 36176661; PMCID: PMC9416821.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Pretransplant Dialysis and Preemptive Transplant in Living Donor Kidney Recipients. Kidney360. 2022 06 30; 3(6):1080-1088. Lai M, Gao Y, Tavakol M, Freise C, Lee BK, Park M. PMID: 35845334; PMCID: PMC9255866.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. The effect of kidney transplantation on left ventricular remodeling and global diastolic strain rate in end-stage renal disease. Echocardiography. 2021 11; 38(11):1879-1886. Lassen MCH, Qasim A, Webber A, Gao Y, Biering-Sørensen T, Park M. PMID: 34713484.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    20. Two Years In: The Development and Basic Characteristics of a National Patient-Powered Registry in ADPKD. Journal of the American Society of Nephrology. 2021 Oct 1; 32(10S):405-405. Hoover HE, Benson BB, Dahl DN, Gitomer GB, Manelli MA, Mrug MM, Park PM, Rusconi RC, Seliger SS, Perrone PR, Watnick WT. .
      View in: Publisher Site   Mentions:
    21. Post-Transplant Cardiovascular Disease. Clin J Am Soc Nephrol. 2021 12; 16(12):1878-1889. Birdwell KA, Park M. PMID: 34556500; PMCID: PMC8729500.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    22. Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients. J Natl Compr Canc Netw. 2020 11; 18(11):1446-1452. Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P. PMID: 33152701.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Design and Basic Characteristics of a National Patient Registry in ADPKD. Journal of the American Society of Nephrology. 2020 Oct 1; 31(10S):501-501. Hoover HE, Baron BD, Benson BB, Gitomer GB, Kleber KK, Manelli MA, Mrug MM, Park PM, Rusconi RC, Seliger SS, Perrone PR, Watnick WT. .
      View in: Publisher Site   Mentions:
    24. Prescription patterns of opioids and non-steroidal anti-inflammatory drugs in the first year after living kidney donation: An analysis of U.S. Registry and Pharmacy fill records. Clin Transplant. 2020 08; 34(8):e14000. Vest LS, Sarabu N, Koraishy FM, Nguyen MT, Park M, Lam NN, Schnitzler MA, Axelrod D, Hsu CY, Garg AX, Segev DL, Massie AB, Hess GP, Kasiske BL, Lentine KL. PMID: 32502285; PMCID: PMC7449599.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    25. Development of renal cysts in a transplanted kidney. Am J Transplant. 2020 06; 20(6):1749-1751. Freise J, Cadwell C, Park M, Freise C. PMID: 32472640.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Molecular characterization of a gastric cancer transmitted from an organ donor to four transplant recipients. Journal of Clinical Oncology. 2020 Feb 1; 38(4_suppl):414-414. Atreya AC, Park PM, Grenert GJ, Behr BS, Gonzalez GA, Chou CJ, Maisel MS, Friedlander FT, Freise FC, Shoji SJ, Semrad ST, Chin-Hong CP, Collisson CE, Van Ziffle VJ. .
      View in: Publisher Site   Mentions:
    27. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. Kidney Int Rep. 2020 Mar; 5(3):278-288. Freedman BI, Moxey-Mims MM, Alexander AA, Astor BC, Birdwell KA, Bowden DW, Bowen G, Bromberg J, Craven TE, Dadhania DM, Divers J, Doshi MD, Eidbo E, Fornoni A, Gautreaux MD, Gbadegesin RA, Gee PO, Guerra G, Hsu CY, Iltis AS, Jefferson N, Julian BA, Klassen DK, Koty PP, Langefeld CD, Lentine KL, Ma L, Mannon RB, Menon MC, Mohan S, Moore JB, Murphy B, Newell KA, Odim J, Ortigosa-Goggins M, Palmer ND, Park M, Parsa A, Pastan SO, Poggio ED, Rajapakse N, Reeves-Daniel AM, Rosas SE, Russell LP, Sawinski D, Smith SC, Spainhour M, Stratta RJ, Weir MR, Reboussin DM, Kimmel PL, Brennan DC. PMID: 32154449; PMCID: PMC7056919.
      View in: PubMed   Mentions: 36  
    28. Cardiac function assessed by myocardial deformation in adult polycystic kidney disease patients. BMC Nephrol. 2019 08 16; 20(1):324. Lassen MCH, Qasim AN, Biering-Sørensen T, Reeh JLT, Watnick T, Seliger SL, Chen H, Sawan MA, Nguyen D, Li Y, Hong SN, Park M. PMID: 31419965; PMCID: PMC6697983.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Development and Validation of a Pragmatic Electronic Phenotype for CKD. Clin J Am Soc Nephrol. 2019 09 06; 14(9):1306-1314. Norton JM, Ali K, Jurkovitz CT, Kiryluk K, Park M, Kawamoto K, Shang N, Navaneethan SD, Narva AS, Drawz P. PMID: 31405830; PMCID: PMC6730512.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    30. Postdonation eGFR and New-Onset Antihypertensive Medication Use After Living Kidney Donation. Transplant Direct. 2019 Aug; 5(8):e474. Lentine KL, Holscher CM, Naik AS, Lam NN, Segev DL, Garg AX, Axelrod D, Xiao H, Henderson ML, Massie AB, Kasiske BL, Hess GP, Hsu CY, Park M, Schnitzler MA. PMID: 31576370; PMCID: PMC6708633.
      View in: PubMed   Mentions:
    31. Primary aldosteronism associated with a germline variant in CACNA1H. BMJ Case Rep. 2019 May 23; 12(5). Wulczyn K, Perez-Reyes E, Nussbaum RL, Park M. PMID: 31126930; PMCID: PMC6536178.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    32. The Effect of Enlarged Kidneys on Calculated Body Mass Index Categorization in Transplant Recipients With ADPKD. Kidney Int Rep. 2019 Apr; 4(4):606-609. Freise J, Tavakol M, Gao Y, Klein O, Lee BK, Freise C, Park M. PMID: 30993236; PMCID: PMC6451113.
      View in: PubMed   Mentions: 4  
    33. Subclinical metabolic and cardiovascular abnormalities in autosomal dominant polycystic kidney disease
. Clin Nephrol. 2018 Oct; 90(4):237-245. Chirumamilla R, Mina D, Siyahian S, Park M. PMID: 30106364.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    34. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. Am J Kidney Dis. 2019 01; 73(1):51-61. Weiner DE, Park M, Tighiouart H, Joseph AA, Carpenter MA, Goyal N, House AA, Hsu CY, Ix JH, Jacques PF, Kew CE, Kim SJ, Kusek JW, Pesavento TE, Pfeffer MA, Smith SR, Weir MR, Levey AS, Bostom AG. PMID: 30037726; PMCID: PMC6309643.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    35. "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis. Hepatology. 2018 11; 68(5):1953-1960. Cullaro G, Park M, Lai JC. PMID: 29698588; PMCID: PMC6203679.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    36. Recurrent Renal Cysts in a Transplanted Kidney. Ann Intern Med. 2018 11 06; 169(9):657-658. Park M, Nussbaum RL. PMID: 29971405.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Associations of TNFR1 with kidney function outcomes by age, gender, and baseline kidney function status: Data from the Heart and Soul Study. Data Brief. 2017 Oct; 14:366-370. Park M, Maristany D, Huang D, Shlipak MG, Whooley M. PMID: 28831402; PMCID: PMC5552376.
      View in: PubMed   Mentions:
    38. Understanding barriers to medication, dietary, and lifestyle treatments prescribed in polycystic kidney disease. BMC Nephrol. 2017 Jul 05; 18(1):214. Tran WC, Huynh D, Chan T, Chesla CA, Park M. PMID: 28679364; PMCID: PMC5498983.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    39. Associations of tumor necrosis factor alpha receptor type 1 with kidney function decline, cardiovascular events, and mortality risk in persons with coronary artery disease: Data from the Heart and Soul Study. Atherosclerosis. 2017 Aug; 263:68-73. Park M, Maristany D, Huang D, Shlipak MG, Whooley M. PMID: 28601698; PMCID: PMC6317896.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    40. Urine Kidney Injury Biomarkers and Risks of Cardiovascular Disease Events and All-Cause Death: The CRIC Study. Clin J Am Soc Nephrol. 2017 May 08; 12(5):761-771. Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X, Mifflin T, Waikar SS, Sabbisetti VS, Bonventre JV, Coresh J, Nelson RG, Kimmel PL, Kusek JW, Rahman M, Schelling JR, Vasan RS, Liu KD, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators, CKD Biomarkers Consortium. PMID: 28254771; PMCID: PMC5477212.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    41. Association of Peak Changes in Plasma Cystatin C and Creatinine With Death After Cardiac Operations. Ann Thorac Surg. 2016 Apr; 101(4):1395-401. Park M, Shlipak MG, Thiessen-Philbrook H, Garg AX, Koyner JL, Coca SG, Parikh CR, Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury Consortium. PMID: 26921980; PMCID: PMC4803601.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Associations of kidney injury markers with subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Clin Nephrol. 2015 Dec; 84(6):358-63. Park M, Shlipak MG, Vittinghoff E, Katz R, Siscovick D, Sarnak M, Lima JA, Hsu CY, Peralta CA. PMID: 26558369; PMCID: PMC4776253.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. J Am Soc Nephrol. 2016 Jul; 27(7):2109-21. Bansal N, Carpenter MA, Weiner DE, Levey AS, Pfeffer M, Kusek JW, Cai J, Hunsicker LG, Park M, Bennett M, Liu KD, Hsu CY. PMID: 26538631; PMCID: PMC4926968.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    44. Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study. Atherosclerosis. 2015 Dec; 243(2):546-52. Park M, Kulkarni A, Beatty A, Ganz P, Regan M, Vittinghoff E, Whooley M. PMID: 26523992; PMCID: PMC4663109.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    45. Prevalence of abdominal aortic calcifications in older living renal donors and its effect on graft function and histology. Transpl Int. 2015 Oct; 28(10):1172-8. Wu EH, Wojciechowski D, Chandran S, Yeh BM, Park M, Westphalen A, Wang ZJ. PMID: 26011061.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. Islands in the stream: the risk of kidney disease from cardiovascular disease. Am J Kidney Dis. 2015 May; 65(5):647-9. Park M. PMID: 25919498.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults. Clin J Am Soc Nephrol. 2015 Feb 06; 10(2):205-14. Bansal N, Katz R, Dalrymple L, de Boer I, DeFilippi C, Kestenbaum B, Park M, Sarnak M, Seliger S, Shlipak M. PMID: 25605700; PMCID: PMC4317737.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    48. Relationship between kidney disease and endothelial function in peripheral artery disease. J Vasc Surg. 2014 Dec; 60(6):1605-11. Chong KC, Owens CD, Park M, Alley HF, Boscardin WJ, Conte MS, Gasper WJ, Grenon SM. PMID: 25441679; PMCID: PMC4254442.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    49. Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study. Am Heart J. 2014 Dec; 168(6):931-9.e2. Park M, Vittinghoff E, Shlipak MG, Mishra R, Whooley M, Bansal N. PMID: 25458658; PMCID: PMC4254643.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    50. Abstract 314: Determinants of Endothelial Dysfunction in Peripheral Artery Disease: Importance of Kidney Disease. Arteriosclerosis Thrombosis and Vascular Biology. 2014 May 1; 34(suppl_1). Chong CK, Owens OC, Park PM, Alley AH, Conte CM, Gasper GW, Grenon GM. .
      View in: Publisher Site   Mentions:
    51. An ACE in the hole for patients with advanced chronic kidney disease? JAMA Intern Med. 2014 Mar; 174(3):355-6. Park M, Hsu CY. PMID: 24342932.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis. 2014 Apr; 63(4):567-72. Parikh CR, Butrymowicz I, Yu A, Chinchilli VM, Park M, Hsu CY, Reeves WB, Devarajan P, Kimmel PL, Siew ED, Liu KD, ASSESS-AKI Study Investigators. PMID: 24200462; PMCID: PMC3969397.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    53. Role of soluble endothelial cell-selective adhesion molecule biomarker in albuminuria and kidney function changes in patients with coronary artery disease: the Heart and Soul Study. Arterioscler Thromb Vasc Biol. 2014 Jan; 34(1):231-6. Park M, Vittinghoff E, Ganz P, Peralta CA, Whooley M, Shlipak MG. PMID: 24177327; PMCID: PMC4059045.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    54. Urine Biomarkers Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) Have Different Patterns in Heart Failure Exacerbation. Biomark Insights. 2013; 8:15-8. Park M, Vittinghoff E, Liu KD, Shlipak MG, Hsu CY. PMID: 23531625; PMCID: PMC3603387.
      View in: PubMed   Mentions: 7  
    55. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol. 2012 Oct; 23(10):1725-34. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG, Chronic Renal Insufficiency Cohort (CRIC) Study Group. PMID: 22935481; PMCID: PMC3458463.
      View in: PubMed   Mentions: 141     Fields:    Translation:Humans
    56. Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2012 Jul; 7(7):1137-44. Park M, Shlipak MG, Katz R, Agarwal S, Ix JH, Hsu CY, Peralta CA. PMID: 22580783; PMCID: PMC3386670.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    57. Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review. Am J Nephrol. 2010; 31(5):408-18. Park M, Coca SG, Nigwekar SU, Garg AX, Garwood S, Parikh CR. PMID: 20375494; PMCID: PMC2883845.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    58. Pheochromocytoma presenting with myocardial infarction, cardiomyopathy, renal failure, pulmonary hemorrhage, and cyclic hypotension: case report and review of unusual presentations of pheochromocytoma. J Clin Hypertens (Greenwich). 2009 Feb; 11(2):74-80. Park M, Hryniewicz K, Setaro JF. PMID: 19222671; PMCID: PMC8673003.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    59. Preservation of fertility and the impact of subsequent pregnancy in patients with premenopausal breast cancer. Semin Oncol. 2006 Dec; 33(6):664-71. Park M, Davidson R, Fox K. PMID: 17145346.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans